Macrogenics (MGNX) Depreciation & Amortization (CF) (2012 - 2026)
Macrogenics (MGNX) posted quarterly Depreciation & Amortization (CF) of $1.7 million for Q1 2026, down 4.74% year-over-year from $1.8 million in Q1 2025, and down 1.06% quarter-over-quarter from $1.7 million in Q4 2025.
Macrogenics (MGNX) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Depreciation & Amortization (CF) for 15 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 4.74% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $7.1 million (down 5.11% YoY), while the FY2025 annual figure was $7.2 million, down 4.88% from the prior year.
- Depreciation & Amortization (CF) slipped to $1.7 million in Q1 2026 per MGNX's latest filing, from $1.7 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $3.2 million in Q4 2022 and bottomed at $1.7 million in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $2.2 million across 5 years, with a median of $1.9 million in 2025.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) grew 9.45% — and 2023, when it plunged 41.19%.
- Macrogenics' Depreciation & Amortization (CF) stood at $3.2 million in 2022, then tumbled by 41.19% to $1.9 million in 2023, then gained by 8.05% to $2.1 million in 2024, then fell by 16.95% to $1.7 million in 2025, then slipped by 1.06% to $1.7 million in 2026.
- Business Quant data shows MGNX's Depreciation & Amortization (CF) at $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 1.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.69 Mn |
| Mar 31, 2026 | 1.69 Mn |
| Dec 31, 2025 | 1.71 Mn |
| Dec 31, 2025 | 1.71 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | 1.91 Mn |
| Mar 31, 2025 | 1.77 Mn |
| Mar 31, 2025 | 1.77 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | 1.84 Mn |
| Mar 31, 2024 | 1.84 Mn |
| Dec 31, 2023 | 1.90 Mn |
| Dec 31, 2023 | 1.90 Mn |